Swiss-American CDMO
United States
Program data pending ClinicalTrials.gov matching
Profiled
Not yet scored
✓ FDA Inspections (1)
○ Clinical Trials
○ SEC Filings
○ Press
○ EMA GMP
○ MHRA GMP
✓ HC GMP (7)
Quick Facts: Swiss-American CDMO
- Signal Score
- Profiled, not yet scored. Scores are published after regulatory evidence is attached and reviewed. How scoring works
- Headquarters
- United States
- Website
- https://www.sacdmo.com/
- Modalities
- Semi-solids & Liquids, Packaging & Labeling
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
About Swiss-American CDMO
Swiss-American CDMO is a contract development and manufacturing organization (CDMO). Capabilities: Semi-solids & Liquids, Packaging & Labeling. 1 manufacturing site registered with the U.S. FDA and Health Canada. Website: https://www.sacdmo.com/
Signal Score
Profiled, not yet scored.
Scores are published after regulatory evidence is attached and reviewed.
How scoring works
Swiss-American CDMO FDA Inspection History
2022-03
NAI
VAI
OAI
| Date | Site | Type | Observations | Classification |
|---|---|---|---|---|
| 2022-03-31 |
Swiss American CDMO, LLC
Carrollton, Texas
Company-level
|
Drug Quality Assurance | Yes | Voluntary Action Indicated (VAI) |
Source: FDA Data Dashboard · Retrieved Oct 31, 2026
Swiss-American CDMO FDA 483 Findings 14 observations · 2022-03-31 → 2024-12-16 ?
By subsystem
By severity
- 4 — Serious: 2
- 3 — Moderate: 2
- 2 — Minor: 10
- Repeat observations: 1
Most severe findings
-
Lack of or inadequate process validation
"A process whose results cannot be fully verified by subsequent inspection and test has not been adequately validated according to established procedures."
-
Lack of or inadequate process validation
"A process whose results cannot be fully verified by subsequent inspection and test has not been adequately validated according to established procedures."
-
Lack of or inadequate procedures
"Procedures for corrective and preventive action have not been adequately established."
Hiring Activity Beta
Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data yet. We haven't found a public jobs feed for this company.
Source:
public careers pages
· Checked Oct 30, 2026
Frequently Asked Questions About Swiss-American CDMO
How many FDA inspections does Swiss-American CDMO have on record?
CDMO Signal tracks 1 FDA inspection for Swiss-American CDMO, sourced from the FDA inspection database. See the full inspection history above.
Has Swiss-American CDMO received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Swiss-American CDMO.
Does Swiss-American CDMO have a CDMO Signal Score?
Not yet. Swiss-American CDMO is profiled, not yet scored. Scores are published after regulatory evidence is attached and reviewed.
Evaluating Swiss-American CDMO for a manufacturing program?
Use the free AI matchmaker to compare Swiss-American CDMO against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
Similar CDMOs
PTI Georgia (Pharma Tech Industries)
United States
Oral Solid Dose, Semi-solids & Liquids, Packaging & Labeling
Pierre Fabre CDMO
Castres, France
Oral Solid Dose, Finished Dosage Forms, Non-sterile Liquids, Semi-solids & Liquids, Small Molecule API, High-Potency APIs, Packaging & Labeling
FIDELIO Healthcare Limburg
Limburg an der Lahn, Germany
Non-sterile Liquids, Semi-solids & Liquids, Oral Solid Dose, Controlled Substances, Packaging & Labeling
DMX Pharma
Milan, Italy
Oral Solid Dose, Oral Liquids, Semi-solids & Liquids, Softgels, Sterile Injectables, Inhalation & Nasal, Packaging & Labeling
Hänseler
Herisau, Switzerland
Semi-solids & Liquids, Oral Liquids, Packaging & Labeling
Compare Swiss-American CDMO with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.